Scailyte AG
Predictive biomarkers, fueling next-gen pharma pipelines.
Scailyte pioneers single-cell biomarker discovery as this technology enters clinical trials. Our proprietary computational platform creates high-value IP and clinical assets in autoimmunity and oncology, with a model targeting Tempus AI's 10x+ ROI on data.
Our model is validated by a successful asset divestment and a pilot with a top-10 pharma now progressing to a multi-year strategic partnership. Our new IBD program leverages a cohort built on CHF 12M in public funds, plus a CHF 1M grant for our work, with LOIs currently in negotiation with two top pharma companies.
We are positioning for a Series B to scale our pharma business, targeting CHF 100M in TCV by 2027, and project a 5x-10x ROI via strategic acquisition.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
04.01.2024
Hera Biotech acquires endometriosis diagnostic assets from Scailyte (startupticker.ch)
05.12.2023
Scailyte reaches USD 8 million in Series A (startupticker.ch)
05.12.2023
Scailyte bolsters Series A funding to USD 8 Million, accelerating the innovation in the immuno-oncology landscape (venturelab.swiss)
12.05.2023
Startups welcome seasoned industry leaders to their board (startupticker.ch)
Last Tweets
01.03.2021
Co-development & commercialization with a UK diagnostics company
01.10.2019
Received grant from Innosuisse for a third biomarker discovery project in partnership with Inselspital, Bern
No Jobs
Videos
Company Presentation
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Scailyte AG
Predictive biomarkers, fueling next-gen pharma pipelines.
Website:
www.scailyte.com
Headquarter:
Basel
Foundation Date:
June 2017
Technology:
- Biotech
Sectors:
- Bioinformatics
- Big Data
- Biotech
- Cancer
- Digital Health
- Diagnostics
- Machine Learning / AI
- Software
Support received
